Benda’s Jiangling Plant Gets Production Approval
This article was originally published in PharmAsia News
SHANGHAI - Benda's Jiangling plant has received approval from China's State FDA for the production of active pharmaceutical ingredients, the company announced Jan. 22
You may also be interested in...
SHANGAHI - Benda has recognized $1.3 million in revenues from an order worth $3.8 million placed at a recent conference for its cancer gene therapy Gendicine, the company announced Dec 5
SHANGHAI - China-Based Benda Pharmaceuticals anticipates 2008 approval from India's Central Drugs Control Organization for its gene therapy product Gendicine for treatment of head and neck cancer. The company filed its application for the recombinant human Ad-p53 injection in November
SHANGHAI - China's State Food and Drug Administration issued revised good manufacturing practice inspectional guidelines Oct. 24 in an effort to increase quality systems standards for pharmaceutical manufacturers. The new guidelines are scheduled to go into effect Jan. 1, replacing the current GMP inspectional guidelines, which were implemented in 1998